Catalent Stock

Catalent FCF Conversion

Delisted·Dec 17, 2024

The FCF Conversion Rate (FCF/EBITDA) of Catalent (CTLT) as of Aug 4, 2026 is 5.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 138.79 % — a change of -95.92% (lower).

FCF Conversion

5.66 %

YoY

-95.92%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Catalent is 2026 5.66 % . FCF Conversion Rate (FCF/EBITDA) of Catalent was 2025 138.79 % . It decreases by -95.92% lower compared to the previous year.
Access this data via the Eulerpool API

Catalent Stock analysis

What does Catalent do? Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Catalent stock

FCF Conversion Rate (FCF/EBITDA) of Catalent is 5.66 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Catalent changed from 138.79 % to 5.66 %, representing a -95.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Catalent since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Catalent with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Catalent

All Key Metrics — Catalent